BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax represents a novel class of orally available selective inhibitors of bcl-2, specifically a BH3 mimetic which antagonises bcl-2 overexpression in CLL and thereby shifts the intracellular balance of bcl-2 activators and inhibitors towards the activation of apoptosis via the mitochondrial pathway.